Size‐Transformable Supramolecular Nanoprodrugs Enable Redox Imbalance Amplification and Cholesterol Modulation to Boost Multidimensional Tumor Immunotherapy
Small · 2026-04 · 22 (22)
DOI: 10.1002/smll.202514467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 17.02.2026. Verfasst von Qi Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hebei Province Key Laboratory of Innovative Drug Research and Evaluation, Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Cholesterol, Immunotherapy, Prodrugs, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Chunyu Project Outstanding Youth Fund of Hebei Medical University.
Abstract (Originalsprache)
Low immunogenicity and highly immunosuppressive tumor microenvironment (TME) present major challenges in immunotherapy, as they restrict T lymphocyte infiltration and activation. Although ferroptosis induction has emerged as a promising approach for enhancing tumor immunogenicity and promoting T cell recruitment, its efficacy is frequently compromised by cholesterol‐driven T cell functional exhaustion. To address these limitations, we engineered tumor‐targeting, TME‐responsive, and size‐switchable supramolecular nanoprodrugs that enable multidimensional immune activation. Nanoprodrugs orchestrate a sophisticated cascade of immune activation through four synergistic mechanisms: 1) size‐switchable disassembly upon glutathione/ cholesterol exposure for deep tumor penetration; 2) redox imbalance driven by reactive nitrogen species accumulation and glutathione depletion via the synergistic action of oxaliplatin, ferrocene, and RRx‐001 for ferroptosis augmentation; 3) immunogenic cell death induction via ferroptosis‐apoptosis to initiate tumor immunity cycle, promoting T cell infiltration; and 4) T cell function reinvigoration with the downregulation of programmed cell death protein 1 and T‐cell immunoglobulin 3 expression through cholesterol depletion in TME. This integrated approach achieved primary and distant tumor growth suppression, established durable immune memory against recurrence, and systemically enhanced the antitumor immunity. By concurrently targeting tumor immunogenicity, TME immunosuppression, and T cell exhaustion, this multidimensional strategy represents a transformative advancement in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hebei Province Key Laboratory of Innovative Drug Research and Evaluation, Hebei Medical University, Shijiazhuang, China.
- The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
- College of Basic Medicine, Hebei Medical University, Shijiazhuang, China.
- Core Facilities and Centers, Hebei Medical University, Shijiazhuang, China.
ORCID-Profile: Lina Zhang
Förderung
- Chunyu Project Outstanding Youth Fund of Hebei Medical University
Zitieren
APA
Zhang, Q., Meng, L., Wang, Z., Fu, Y., Li, L., Zhang, X., Zhang, H., & Zhang, L. (2026). Size‐Transformable Supramolecular Nanoprodrugs Enable Redox Imbalance Amplification and Cholesterol Modulation to Boost Multidimensional Tumor Immunotherapy. Small, 22(22). https://doi.org/10.1002/smll.202514467
Vancouver
Zhang Q, Meng L, Wang Z, Fu Y, Li L, Zhang X, et al. Size‐Transformable Supramolecular Nanoprodrugs Enable Redox Imbalance Amplification and Cholesterol Modulation to Boost Multidimensional Tumor Immunotherapy. Small. 2026;22(22). doi:10.1002/smll.202514467
BibTeX
@article{Zhang2026,
author = {Zhang, Qi and Meng, Lingfeng and Wang, Zilin and Fu, Yan and Li, Luya and Zhang, Xiaoyu and Zhang, Huaxing and Zhang, Lina},
title = {Size‐Transformable Supramolecular Nanoprodrugs Enable Redox Imbalance Amplification and Cholesterol Modulation to Boost Multidimensional Tumor Immunotherapy},
journal = {Small},
year = {2026},
volume = {22},
number = {22},
doi = {10.1002/smll.202514467}
}
EUVIMED